[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroesophageal-reflux-disease-gerd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroesophageal-reflux-disease-gerd":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,54,79,112,142,174,200,225,247,273],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100401388","indiana-university-gastrointestinal-motility-diagnosis-registry-100401388",false,"NCT04506593","Indiana University Gastrointestinal Motility Diagnosis Registry","Gastrointestinal Motility Diagnosis Registry","Inclusion Criteria:\n\n1. Patients who presented to the GI outpatient clinics, in-patient consult service, and outpatient endoscopy centers within the Division of Gastroenterology and Hepatology\n2. Carries a diagnosis of GI motility disorder based on the diagnostic criteria listed in table\n\nExclusion Criteria:\n\n1\\. Coexisting medical conditions that may limiting participation in clinical research trial","ALL",{"count":18,"type":19},5000,"ESTIMATED","10 Years","OBSERVATIONAL","Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to identify the patients with specific disease conditions. It will also help in promoting future research in gastroenterology motility disorders",[24,25,26,27,28,29,30,31,32],"Eosinophilic Esophagitis","Gastroesophageal Reflux Disease (GERD)","Gastroparesis","Functional Vomiting","Irritable Bowel Syndrome (IBS)","Constipation","Chronic Intestinal Pseudo-obstruction","Fecal Incontinence","Small Intestinal Bacterial Overgrowth",[34,35,36,37,38,39,40,26],"Eosinophilic esophagitis","Chronic intestinal pseudo-obstruction","Small Bowel dysmotility","SIBO","Vomiting","Functional dyspepsia","Functional bloating","RECRUITING","2026-06-15",{"date":44,"type":45},"2026-06-16","ACTUAL",{"date":47,"type":45},"2014-11-01",{"date":49,"type":19},"2026-11",{"name":51,"class":52},"Indiana University","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100641843","symptom-severity-posture-pain-and-physical-activity-in-gastroesophageal-reflux-disease-100641843","NCT07643779","Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux Disease","Investigation of Symptom Severity, Posture, Musculoskeletal Pain, and Physical Activity Levels in Patients With Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* Being diagnosed with gastroesophageal reflux disease (GERD)\n* Age between 18 and 65 years\n* Willingness to participate in the study assessments\n\nExclusion Criteria:\n\n* Presence of a diagnosed psychiatric disorder\n* Pregnancy or breastfeeding status","18 Years","65 Years",{"count":64,"type":19},51,"This study is a cross-sectional research designed to investigate symptom severity, posture, musculoskeletal pain, and physical activity levels in individuals with gastroesophageal reflux disease (GERD).",[25,67,68,69],"Symptom","Musculoskeletal Pain","Physical Activity","NOT_YET_RECRUITING","2026-06-11",{"date":42,"type":45},{"date":74,"type":19},"2026-07-01",{"date":76,"type":19},"2026-12-30",{"name":78,"class":52},"Karabuk University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":53},"100077248","esophageal-cancer-risk-registry-100077248","NCT00260585","Esophageal Cancer Risk Registry","Inclusion Criteria:\n\n* Known or suspected esophageal or gastroesophageal junction malignancy\n* Known Barrett's metaplasia\n* Clinical management of symptomatic gastroesophageal reflux disease (GERD)\n* Achalasia\n* Hiatal hernia\n\nExclusion Criteria:\n\n* Elevated pre-operative bloodwork will not have the additional biopsies taken.\n* Platelet count less than 150,000, partial thromboplastin time (PTT) of 50 or above, and\u002For International Normalized Ratio (INR) of 1.8 or above will not have the additional biopsies taken.",{"count":86,"type":19},7000,"The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identifying genetic and behavioral risk factors involved in the development of esophageal cancer might allow for early detection and prevention. Survival and an opportunity for a cure with esophageal cancer will depend greatly on the stage of diagnosis. Tumors can develop changes in their genetic (hereditary) make-up, and these changes can sometimes be seen in normal tissues before the development of cancer. These genetic (hereditary) changes can serve as tumor markers and can be detected using methods that study changes in genetic material like DNA and RNA. The analysis of proteins can provide additional information. By identifying changes in these molecules that are different or altered in cancer, the investigators can use methods and tests for the detection of these changes.",[89,25,90,91,92],"Esophageal Cancer","Esophageal Diseases","Hiatal Hernia","Esophageal Achalasia",[94,95,96,97,98,99,100,101,102],"gastroesophageal reflux disease","GERD","hiatal hernia","achalasia","Barrett's metaplasia","Anti-Reflux Surgery","Known\u002Fsuspected esophageal\u002Fgastroesophageal junction tumor","Esophageal disorders such as Barrett's metaplasia","Symptomatic gastroesophageal reflux disease","2026-04-09",{"date":105,"type":45},"2026-04-14",{"date":107,"type":45},"1999-06",{"date":109,"type":19},"2050-12",{"name":111,"class":52},"University of Pittsburgh",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":141},"100591750","performance-and-safety-of-afluxin-in-patients-with-gastroesophageal-reflux-disease-100591750","NCT06984484","Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease","A Multicenter, RandoMized, Double-blind, Parallel-grOup, Afluxin® Stick Pack vs. Inactive contRol Clinical Investigation to Evaluate the Performance and Safety in Patients With Gastroesophageal Reflux Disease (GERD)","ARMOR","Inclusion Criteria:\n\n1. Male and female patients, aged ≥ 18 years and ≤ 75 years.\n2. Evidence of symptomatic GERD: patients with ongoing heartburn and\u002For regurgitation (with or without dyspepsia symptoms of epigastric pain and\u002For burning) of at least mild to moderate severity or experienced during the least 7 days before starting the treatment, as assessed on a clinical basis by the Investigator.\n3. Patients not pre-treated with PPIs, even for problems different from GERD (e.g., gastroprotection, PPI-based triple or quadruple therapy for eradication of H. pylori), H2RAs, and\u002For with antiacids, alginates or medical devices made of substances (i.e., substance-based medical devices to treat GERD, gastroesophageal reflux and similar conditions) in the last week prior to screening.\n4. Patient has provided written informed consent after being informed of the study procedures and risks prior to any study-related events.\n5. Patients are able to understand and adhere to the study procedures.\n6. Females of childbearing potential must have a negative urine pregnancy test (dipstick) at Visit 1 and currently use or agree to use consistently and correctly (i.e., perfect use) a highly effective or acceptable effective contraceptive method for the individual subject and her partner(s) throughout the study treatment period.\n\nExclusion Criteria:\n\n1. Patient with hypersensitivity to any Afluxin® or inactive control components.\n2. Rhinosinusitis or bronchitis.\n3. Patients with a:\n\n   1. history and\u002For\n   2. symptom profile and\u002For\n   3. discovered on endoscopy suggestive of the following: any other Gastrointestinal (GI) disease, erosive GERD, BE, acute peptic ulcer and\u002For ulcer complications, hiatus hernia with a diameter which exceeds 3 cm, Zollinger-Ellison syndrome, esophageal or gastric cancer, pyloric stenosis, esophageal or gastric surgery, intestinal obstruction, current pernicious anemia, indication for H. pylori eradication therapy, known gastro-intestinal bleeding (hematochezia or hematemesis) within the last 12 months.\n4. Patients diagnosed with functional dyspepsia characterized by postprandial distress syndrome (i.e., bothersome postprandial fullness and\u002For early satiation).\n5. Patients with a history of gastro-esophageal surgery, anti-reflux, or bariatric procedure.\n6. Presence of any active malignancy (except for non-invasive basal or squamous cell carcinoma of the skin).\n7. Patients using any drug that could affect symptoms or affecting the gastrointestinal tract during the last week prior to screening:\n\n   1. prokinetics\n   2. systemic glucocorticosteroids\n   3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)\n8. Patients who are pregnant or lactating.\n9. Patients who are enrolled in or have participated in other clinical trials or investigations within 30 days prior to screening.\n10. Clinically significant or unstable concurrent diseases whose sequelae or treatment might contraindicate study participation or interfere with the study evaluation parameters, as judged by the Investigator.","75 Years",{"count":122,"type":19},208,"INTERVENTIONAL",[125],"NA","Gastroesophageal Reflux Disease (GERD) is a chronic condition in which stomach acid flows back into the esophagus, causing irritation and inflammation. GERD is categorized into Nonerosive Reflux Disease (NERD), Erosive Esophagitis (EE), and Barrett's esophagus (BE). Common symptoms include heartburn and acid regurgitation. Lifestyle factors such as smoking, obesity, and Helicobacter pylori infection can increase the risk of developing GERD. The clinical management of GERD typically involves Proton Pump Inhibitors (PPIs) therapy, which, although effective, may not benefit all patients and can be associated with long-term risks. The American College of Gastroenterology (ACG) suggests PPIs discontinuation or on-demand therapy for uncomplicated GERD after an 8-week trial. However, evidence indicates that PPIs are used more frequently, often long-term and in high doses, and not necessarily according to recommendations. Moreover, the availability of Over-The-Counter (OTC) PPIs has led to prolonged use by patients without medical guidance. Concerns have been raised due to potential side effects of long-term PPIs use, including enteric, respiratory, and urinary tract infections, as well as an increased risk of vitamin and mineral deficiencies and osteoporosis.\n\nAlternatives to PPIs include Histamine-2 Receptor Antagonists (H2RAs), antacids and alginate-based formulations. Among OTC treatments, medical devices formulated with natural components are also gaining attention for their potential performance and tolerability in managing mild to moderate GERD symptoms. These alternatives could address the unmet needs of NERD patients, especially those with a low response to PPIs treatment and provide an option without the potential side effects of prolonged PPIs use. Afluxin® is a class III medical device, containing functional substances (tamarind seed polysaccharide, pea protein and polyacrylic acid), formulated for the treatment of mild to moderate GERD. Preclinical data have shown that Afluxin® is able to create a protective barrier over the gastroesophageal epithelium, preventing reflux damage. In vitro studies suggest that Afluxin® effectively binds to the esophageal and gastric mucosa, reducing abnormal permeability caused by acid reflux. Moreover, in vivo evidence shows that Afluxin® can increase gastric pH, reduce epigastric pain, esophageal damage, and inflammatory markers associated with GERD. Given the encouraging results obtained in preclinical investigations, this study is designed to provide clinical evidence to support the performance and safety of Afluxin® in reducing gastrointestinal symptoms of patients with mild to moderate GERD in a multicenter, randomized, double-blind, parallel-group, Afluxin® stick pack vs. inactive control clinical investigation.",[25],[129,95,130],"Gastroesophageal Reflux Disease","Afluxin","2026-04-07",{"date":133,"type":45},"2026-04-08",{"date":135,"type":45},"2025-07-02",{"date":137,"type":19},"2026-06",{"name":139,"class":140},"Devintec Sagl","INDUSTRY",7,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":123,"phases":152,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100606722","effect-of-breathing-training-on-symptoms-of-gastroesophageal-reflux-disease-100606722","NCT07179250","Effect of Breathing Training on Symptoms of Gastroesophageal Reflux Disease","Effect of Breathing Training on Symptoms of Gastroesophageal Reflux Disease: A Parallel Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 20 to 80 years\n* Endoscopic finding of reflux esophagitis (LA grade A) with proton pump inhibitor (PPI) use \\> 2 months, or 24-hour pH monitoring showing acid exposure time (AET) \\> 6%, or endoscopic diagnosis of reflux esophagitis LA grade B or higher\n* Willingness to comply with the full training and follow-up protocol\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* History of anti-reflux surgery\n* Severe cardiopulmonary dysfunction or respiratory disease\n* Inability to perform the training exercises or attend follow-up visits","20 Years","80 Years",{"count":64,"type":19},[125],"The goal of this clinical trial is to evaluate whether two types of breathing training can improve symptoms of gastroesophageal reflux disease (GERD) in adults.\n\nThe main research questions are:\n\n* Do volume-oriented incentive spirometry (VIS) or diaphragmatic breathing exercise (DBE) improve GERD symptoms compared with usual care?\n* Do these breathing exercises reduce the symptoms of GERD?\n* Does volume-oriented incentive spirometry (VIS) produce greater improvement in GERD symptoms compared with DBE?\n* Do these exercises increase the strength of the lower esophageal sphincter (LES)?\n\nResearchers will compare VIS training, DBE training, and usual care to determine whether breathing training can serve as a safe and effective non-pharmacological treatment option for GERD.\n\nParticipants will:\n\n* Be randomly assigned to VIS training, DBE training, or usual care\n* Perform their assigned breathing training (if in the intervention group) twice daily for 6 weeks\n* Attend study visits at baseline and at week 7 for questionnaires and esophageal function tests\n* Keep a diary of their symptoms and breathing practice",[155,156,25,157],"Incentive Spirometer","Diaphragmatic Breathing","Breath Exercise",[95,129,159,156,160,155,161,162,163,164],"Acid Reflux","Breathing Training","Volume-Oriented Incentive Spirometry","GERDQ","Gastroesophageal Reflux Disease Questionnaire","breath exercise","2025-09-23",{"date":167,"type":45},"2025-09-26",{"date":169,"type":19},"2025-09",{"date":171,"type":19},"2026-05",{"name":173,"class":52},"Changhua Christian Hospital",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":150,"enrollmentInfo":182,"targetDuration":4,"studyType":123,"phases":184,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":53},"100606489","endoscopic-cardial-constriction-ligation-eccl-for-refractory-gerd-using-a-disposable-endoscope-100606489","NCT07176221","Endoscopic Cardial Constriction Ligation (ECCL) for Refractory GERD Using a Disposable Endoscope","Safety and Efficacy of Endoscopic Cardial Constriction Ligation （ECCL） With a Novel Disposable Endoscope: A Multicenter Randomized Controlled Trial","ECCL","Inclusion Criteria:\n\n* (1) Age 18-80 years;\n* (2) Disease duration ≥6 months, with typical symptoms such as acid regurgitation and heartburn, and a confirmed diagnosis of GERD;\n* (3) GERD patients whose symptoms are not relieved after 8 weeks of continuous double-dose acid-suppressive therapy;\n* (4) Willing to participate in the study and have signed the informed consent form.\n\nExclusion Criteria:\n\n* (1) Patients with precancerous lesions such as early esophageal cancer or Barrett's esophagus \\>3 cm, or advanced upper gastrointestinal cancer identified on endoscopy;\n* (2) Patients with hiatal hernia ≥2 cm, severe reflux esophagitis (LA-C or LA-D grade), esophageal or gastric varices, esophageal ulcer or stenosis, or a history of esophageal or gastric surgery;\n* (3) Patients with esophageal motility disorders such as achalasia or diffuse esophageal spasm, rheumatic diseases such as systemic sclerosis or Sjögren's syndrome, or eosinophilic esophagitis;\n* (4) Patients with a history of endoscopic or surgical anti-reflux procedures;\n* (5) Patients with coagulation disorders, severe cardiopulmonary diseases, or inability to tolerate anesthesia, endoscopy, or treatment;\n* (6) Women in the puerperium.",{"count":183,"type":19},46,[125],"This study will recruit patients aged 18-80 with refractory gastroesophageal reflux disease (GERD). These patients had a disease course of more than six months, experienced typical symptoms such as acid reflux and heartburn, and had no symptom relief after taking a double dose of acid-suppressing medication for eight consecutive weeks. All eligible participants will undergo Endoscopic Cardial Constriction Ligation (ECCL) using a disposable endoscope. The procedure will follow a standardized protocol: mucosal and muscle layers of the cardia will be ligated at the lesser curvature, posterior wall, and greater curvature, with the ligated tissue at the greater curvature secured by a hemostatic clip. All patients will receive acid-suppressing therapy post-surgery and will be followed up at three and six months. The follow-ups will assess their GERD-Q scores, symptom relief, and incidence of complications.",[25],[188,189,190],"Gastroesophageal Reflux Disease (GERD).","Endoscopic cardia constriction ligation (ECCL)","novel disposable endoscope","2025-09-09",{"date":193,"type":45},"2025-09-16",{"date":195,"type":19},"2025-10-01",{"date":197,"type":19},"2028-06-30",{"name":199,"class":52},"Ying Zhu",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":207,"sex":16,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":123,"phases":212,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":53},"100586496","phase-1-a-study-to-compare-pkpd-characteristics-and-safety-profiles-between-ad-120-and-ad-120a-100586496","NCT06916130","A Study to Compare PK\u002FPD Characteristics and Safety Profiles Between AD-120 and AD-120A","A Randomized, Open-label, Multiple Oral-dose, 2x2 Crossover Clinical Trial to Compare the Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a AD-120 and AD-120A in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50.0kg and equal to or less than 90.0kg and Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 and equal to or less than 50 in healthy volunteers at the time of screening visit\n* Negative result from Serum Helicobacter pylori antibody at the time of screening visit\n\nExclusion Criteria:\n\n* Patients with trouble performing pH monitor catheter",true,"19 Years","50 Years",{"count":211,"type":19},48,[213],"PHASE1","Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.",[25],"2025-03-31",{"date":218,"type":45},"2025-04-08",{"date":220,"type":19},"2025-04-21",{"date":222,"type":19},"2025-09-01",{"name":224,"class":140},"Addpharma Inc.",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":232,"targetDuration":234,"studyType":21,"phases":4,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":246},"100506113","post-market-registry-for-the-evaluation-of-refluxstop-in-gerd-treatment-100506113","NCT05870163","Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment","A Post-market Registry Study to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice","Inclusion Criteria:\n\n1. Willing and able to provide informed consent and to participate in the registry study,\n2. Patient's age ≥ 18 years or according to local legal age of adulthood if older,\n3. Documented GERD present for \\> 6 months,\n4. Patient has a 24-hour pH monitoring proven GERD with pH and\u002For impedance pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be \\\u003C4 for \\>4.5% of time during a 24-hour monitoring and\u002For total reflux episodes of acid \\>55 or weakly acid \\>26 for \\>5 seconds at 5 cm above LES)\n5. Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator.\n\nExclusion criteria:\n\n1. Presence of para-esophageal hernia or sliding hernia \\> 3 centimeters,\n2. Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed,\n3. History of bariatric surgery wherein the stomach fundus has been extirpated,\n4. Female patients who are pregnant or nursing,\n5. Known sensitivity or allergies to silicone materials,\n6. Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry study procedure (as outlined in the IFU);\n7. Patients that are unable to comply with the registry study requirements, (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the registry study according to the investigator's judgement).",{"count":233,"type":19},2500,"5 Years","This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.",[25],"2025-03-26",{"date":239,"type":45},"2025-04-01",{"date":241,"type":45},"2023-02-20",{"date":243,"type":19},"2029-12-31",{"name":245,"class":140},"Implantica CE Reflux Ltd.",6,{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":95,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":123,"phases":257,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":53},"100583041","efficacy-of-inspiratory-muscle-training-associated-with-manual-techniques-in-individuals-with-gerd-100583041","NCT06871163","EFFICACY OF INSPIRATORY MUSCLE TRAINING ASSOCIATED WITH MANUAL TECHNIQUES IN INDIVIDUALS WITH GERD","EFFICACY OF INSPIRATORY MUSCLE TRAINING ASSOCIATED WITH MANUAL TECHNIQUES FOR THE LOWER ESOPHAGEAL SPHINCTER AND DIAPHRAGMATIC RELEASE IN INDIVIDUALS WITH GASTROESOPHAGEAL REFLUX DISEASE: A RANDOMIZED CLINICAL TRIAL","Inclusion Criteria:\n\n* Individuals diagnosed with gastroesophageal reflux disease (GERD)\n* using 20 mg of proton pump inhibitors (PPIs).\n\nExclusion Criteria:\n\n* Individuals with a hiatal hernia \\>3 cm,\n* chronic lung diseases (chronic obstructive pulmonary disease and interstitial lung diseases)\n* severe heart diseases,\n* history of previous abdominal and\u002For thoracic surgeries, rib fractures within the past year,\n* severe osteoporosis\n* BMI \\>30 kg\u002Fm²","74 Years",{"count":256,"type":19},60,[125],"The objective of this clinical trial is to investigate the efficacy of inspiratory muscle training (IMT) combined with manual techniques for the lower esophageal sphincter (MTLES) and diaphragmatic release (DRT) in patients with Gastroesophageal Reflux Disease (GERD). The main questions it aims to answer are:\n\n1. If the combination of IMT, DRT, and MTLES can improve GERD symptoms and patients' quality of life.\n2. If the home-based IMT protocol, with weekly adjustments, and the manual techniques applied twice a week can have a positive impact on various clinical measures, such as pressure at the lower esophageal sphincter, reflux episodes, and quality of life.\n\nThe researchers will compare three groups: Group 1 (IMT), Group 2 (IMT + DRT + MTLES), and Group 3 (control, sham), to see if the group receiving IMT combined with DRT and MTLES shows greater improvements compared to the control group.\n\nParticipants will perform inspiratory muscle training at home, following a protocol adjusted weekly, and will receive manual techniques twice a week.",[25],[261,262,263],"inspiratory muscle training (IMT)","diaphragmatic release","manual techniques for the lower esophageal sphincter","2025-03-06",{"date":266,"type":45},"2025-03-11",{"date":268,"type":19},"2025-04",{"date":270,"type":19},"2027-02",{"name":272,"class":52},"Universidade Federal de Pernambuco",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":279,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":123,"phases":283,"briefSummary":285,"conditions":286,"keywords":287,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":53},"100559447","phase-4-clinical-study-evaluating-the-role-of-vonoprazan-versus-pantoprazole-in-patients-with-gastroesophageal-reflux-disease-100559447","NCT06564246","Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* Age 17-60 years.\n* Both genders.\n* Patients with a score ≥ 8 on the Gastroesophageal Reflux Disease Questionnaire (Gerd Q) are defined as having GERD and will enroll in this study and it will be done at baseline and after 8 weeks.\n\nExclusion Criteria:\n\n* Subjects with history of gastrointestinal disease, gastroduodenal surgery, inflammatory bowel disease and Barrett's esophagus.\n* Subjects with an earlier or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders (gastric or duodenal ulcer).\n* Subjects with history of total\u002Fsubtotal gastrectomy and esophageal achalasia.\n* Subjects with Corona virus disease (COVID19).\n* Subjects with major cardiological, respiratory, endocrine metabolic disease and neuro-psychological disease.\n* Pregnancy or lactation.\n* Subjects with total bilirubin level ≥ 1.2 mg\u002Fdl and ALT level \\> 100 IU\u002Fl.\n* Subjects with renal impairment (Crcl less than 30 ml\u002Fmin).\n* Patients receiving atazanavir sulphate, nelfinavir and rilpivirine hydrochloride due to potential drug interactions.","17 Years","60 Years",{"count":282,"type":19},44,[284],"PHASE4","This study aims to investigate the possible efficacy of vonoprazan versus Pantoprazole in patients with gastroesophageal reflux disease.",[25],[288,289,25,290,291],"Vonoprazan","Pantoprazole","Gastrin serum level","E-Cadherin level","2024-12-04",{"date":294,"type":45},"2024-12-05",{"date":296,"type":45},"2024-09-18",{"date":298,"type":19},"2026-10",{"name":300,"class":52},"Tanta University"]